实用临床医药杂志2012，Vol.16Issue(19)：89-90,2.
吉西他滨联合奈达铂治疗晚期非小细胞肺癌疗效评价
Clinical efficacy of gemcitabine combined with nedaplatin in the treatment of advanced non-small cell lung cancer
摘要
Abstract
Objective To explore clinical efficacy of gemcitabine combined with nedaplatin in the treatment of advanced non-small cell lung cancer (NSCLC) . Methods Seventy-two advanced NSCLC patients were randomly divided into nedaplatin group (n =38) and cisplatin group (n = 34). The nedaplatin group received treatment as follows: 40 mg, 0.9% sodium chloride solution 500 mL, TV drop 2 hours, d1 - 3. The cisplatin group: 40 mg add 0.9% sodium chloride solution 500 mL, static drop 2 hours, dl3. Gemcitabine 800 mg/nr was administered in both groups, at dl and d8, 0.9% sodium chloride solution 100 mL, IV drop 2 hours. Curative effect and adverse events 2 weeks after chemotherapy were evaluted. Results Total effective rate was 34.2% in the nedaplatin group, and 34. 6% in the cisplatin group. There were no significant differences. Conclusion Gemcitabine combined with nedaplatin has similar efficacy with that of gemcitabine combined with cisplatin in the treatment of advanced NSCLC. There are less adverse intestinal reactions caused by nedaplatin.关键词
非小细胞肺癌/吉西他滨/奈达铂/疗效/毒性Key words
non-small cell lung carcinoma/ gemcitabine/ nedaplatin/ clinical efficacy/ toxicity分类
医药卫生引用本文复制引用
成卫,王彩英..吉西他滨联合奈达铂治疗晚期非小细胞肺癌疗效评价[J].实用临床医药杂志,2012,16(19):89-90,2.基金项目
中国高校医学期刊临床专项资金(11220204) （11220204）
